Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARVIN ZELKOWITZ

NPI
1730189259
CMS profile
214975
Location
FLOSSMOOR, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$23.74

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $23.74 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
CATALYST PHARMACEUTICALS, INC. $23.74 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARVIN ZELKOWITZ

NPI 1730189259 · CMS profile ID 214975

FLOSSMOOR, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730189259?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARVIN ZELKOWITZ, NPI 1730189259, CMS profile ID 214975. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730189259?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MARVIN ZELKOWITZ, NPI 1730189259, CMS profile ID 214975. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730189259?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MARVIN ZELKOWITZ, NPI 1730189259, CMS profile ID 214975, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1730189259?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $23.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CATALYST PHARMACEUTICALS, INC. $23.7401/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 730358987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,001.01 52
PY2020 $23.74 1
PY2023 $60.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $26,363.00 3
PY2021 Principal investigator $9,910.74 16
PY2020 Recipient $756.00 9
PY2020 Principal investigator $329,211.36 6
PY2019 Recipient $75.00 1
PY2019 Principal investigator $739,214.60 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

16 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $84.00 12/31/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842918679
Principal investigator 1 EMD Serono, Inc. $84.00 11/30/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842917641
Principal investigator 1 EMD Serono, Inc. $84.00 10/29/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842917439
Principal investigator 1 EMD Serono, Inc. $84.00 09/30/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842908227
Principal investigator 1 EMD Serono, Inc. $84.00 08/31/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842907829
Principal investigator 1 EMD Serono, Inc. $84.00 07/30/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842907529
Principal investigator 1 Novartis Pharmaceuticals Corporation $736.24 07/08/2021 Non-covered Recipient Entity
HEALTH CARE RESEARCH NETWORK
EXPLORING THE SAFETY AND TOLERABILITY OF CONVERSION TO DOSE TITRATED SIPONIMOD IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS A 6 MONTH OPEN LABEL MULTI CENTER PHASE III B STUDY EXPANDED No dispute reported 06/30/2026 800632383
Principal investigator 1 EMD Serono, Inc. $84.00 06/30/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842929177
Principal investigator 1 EMD Serono, Inc. $84.00 05/31/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842929379
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,018.20 05/05/2021 Non-covered Recipient Entity
SOUTH SUBURBAN NEUROLOGY
LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 800642175
Principal investigator 1 EMD Serono, Inc. $84.00 04/30/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842929541
Principal investigator 1 EMD Serono, Inc. $84.00 03/31/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842901257
Principal investigator 1 EMD Serono, Inc. $84.00 02/26/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842903992
Principal investigator 1 EMD Serono, Inc. $84.00 01/29/2021 Non-covered Recipient Entity
Marissa Docter
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib compared with an Interferon Beta-1a (Avonex), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety No dispute reported 06/30/2026 842901173
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,575.00 01/10/2021 Non-covered Recipient Entity
SOUTH SUBURBAN NEUROLOGY
A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED VARIABLE TREATMENT DURATION STUDY EVALUATING THE EFFICACY AND SAFETY OF SIPONIMOD BAF312 IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 800642181
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,573.30 01/01/2021 Non-covered Recipient Entity
HEALTH CARE RESEARCH NETWORK
EXPLORING THE SAFETY AND TOLERABILITY OF CONVERSION TO DOSE TITRATED SIPONIMOD IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS A 6 MONTH OPEN LABEL MULTI CENTER PHASE III B STUDY EXPANDED No dispute reported 06/30/2026 800632391